Andrew Dudum, Hims & Hers CEO

May 21, 2024 11:47 AM EDTUpdated May 21, 09:20 PM

Hims’ push into compounded GLP-1 drugs risks scrutiny from Novo Nordisk

Ngai Yeung

Health Tech Reporter

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.)

The digital health …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Struggling biotechs succumb to icy market, as money dries up and clinical bets don’t pay off

In a first, Sarepta announces platform technology designation for gene therapy vector

Exclusive: After cutting most staff, Casma eyes path to clinic with its first autophagy-boosting drug

AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in rheumatoid arthritis

Vigil drug fails a Phase 2; Merus aims to raise $300M

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...